Novo Nordisk builds new raw material warehouse in Denmark

Published: 7-Sep-2015
Design & Build Finance

New 17,000-pallet facility will handle all the company’s inbound raw materials in the country


Novo Nordisk is investing 500m Danish kroner in a new 19,000m2 warehouse in Hillerød, Denmark.

The warehouse will handle all inbound raw materials for Novo Nordisk's production in Denmark and will have a capacity of around 17,000 pallets.

Novo Nordisk's site in Hillerød currently has approximately 1900 employees, 70 of which will work in the warehouse.

‘The investment in Hillerød underpins our long-term plans to invest in Denmark. Hillerød is a strategic site in Novo Nordisk and we're consolidating our inbound flow of materials at this site,’ said Susanne Hundsbæk-Pedersen, Senior Vice President of Devices and Supply Chain Management, Novo Nordisk.

Groundbreaking took place on 3 September and the warehouse is expected to be fully operational by the end 2017.

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Finance

Novo Holdings completes acquisition of Catalent

Read more
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  5. £20m Scottish oligonucleotide manufacturing innovation centre now under construction The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's biopharmaceutical presence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Manufacturing

Novavax sells protein manufacturing facility to Novo Nordisk for $200m

Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support buildings
Manufacturing

Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m

Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases
Drug Delivery

Novo invests $40m in proteomics technology company

The investment will be used to advance clinical applications of proteomics enabled by Evosep’s standardised liquid chromatography platform
Finance

Novo enters research partnership with Flagship Pioneering

Novo Nordisk will provide funding for initiated research programmes and have an exclusive option to license each programme
Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits
Subscribe now